TRINITI-1 A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor - Triplet with Ribociclib, AfINItor® and AI posT CDK 4/6 Inhibitor

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/16 → 1/1/20

Funding

  • Novartis Pharmaceuticals